Please ensure Javascript is enabled for purposes of website accessibility

Drugmakers Could Lose Their Greatest Weapon

By Brian Orelli, PhD - Updated Apr 5, 2017 at 8:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Congress is thinking about putting limits on direct-to-consumer advertisements.

Pharmaceutical companies are so worried about losing their biggest weapon to increase sales -- direct-to-consumer (DTC) advertisements -- that the industry trade group made a preemptive strike yesterday.

The industry is worried about talk from Representative Henry Waxman, the new chairman of the House Energy and Commerce Committee, which oversees health care issues. Waxman's no friend to the industry -- he's most famous for the Hatch-Waxman Act, which allows generic drug companies like Mylan (NYSE:MYL) and Teva Pharmaceuticals (NASDAQ:TEVA) to bring drugs to the market more quickly. He's planning to resurrect a bill that would give the Food and Drug Administration the authority to ban DTC advertisements in the first few years after approval should the agency feel it would protect public health. Given how safety conscious the FDA has become, a ban seems like a near certainty.

The Pharmaceutical Research and Manufacturers of America's preemptive strike is a set of voluntary guidelines including things like identifying actors if they're not actually doctors, and requiring celebrity endorsers to fess up and say whether they've actually used the product. Wonder if that'll make it hard for companies to find celebrity endorsements for Pfizer's (NYSE:PFE) Viagra, Eli Lilly's (NYSE:LLY) Cialis, and Levitra, which is marketed by GlaxoSmithKline (NYSE:GSK), Schering-Plough (NYSE:SGP), and Bayer? Think Bob Dole's interested in going back to commercials?

Will the new voluntary guidelines keep Congress at bay? Probably not. But the industry hasn't really hindered itself much. For one thing, the guidelines suggest that companies should "consider individually setting specific periods of time for education [of doctors] before launching a branded DTC campaign." That's pretty weak language, guys.

The biggest problem with a moratorium is that it's the first step in complete removal of drug ads from the airwaves. Drugmakers need those ads to get patients into the doctor's office, and without them, sales will suffer.

More Foolishness:

Pfizer, Eli Lilly, and GlaxoSmithKline are Income Investor picks. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is also an Inside Value recommendation, and the Fool owns shares of it. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$304.61 (0.53%) $1.59
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.95 (0.34%) $0.17
Viatris Inc. Stock Quote
Viatris Inc.
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$11.20 (1.82%) $0.20
GSK Stock Quote
$38.30 (-4.32%) $-1.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.